Clinical Trial Detail

NCT ID NCT03155620
Title Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

sarcoma

non-Hodgkin lymphoma

lymphoma

medulloblastoma

hepatoblastoma

rhabdomyosarcoma

neuroectodermal tumor

Advanced Solid Tumor

lymphatic system cancer

Ewing sarcoma

pediatric ependymoma

central nervous system cancer

neuroblastoma

pediatric osteosarcoma

Therapies

Tazemetostat

Larotrectinib

LY3023414

Vemurafenib

Palbociclib

Olaparib

Ulixertinib

Erdafitinib

Selumetinib

Ensartinib

Age Groups: adult child

Additional content available in CKB BOOST